Targeting the TRAIL/death receptor signaling pathway with either recombinant TRAIL or agonistic death receptor antibodies has been considered a promising cancer therapeutic strategy and has been tested in the clinic [20-23]. The gene discussed is TNFSF10; the disease is cancer.